Clinical Trial Update: Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

This document notes a phase 1/2 trial of an antigen-targeted T cell therapy for relapsed/refractory B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Antigen-targeted T cell therapy

Snippet

Sponsor: National University Hospital, Singapore | Conditions: B-cell Lymphoma Refractory | Phase 1, Phase 2 | Status: RECRUITING